Oyster Point Pharma, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey Nau
- Full Time Employees
- 303
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 202 Carnegie Ctr Ste 109 Princeton NJ United States of America 08540
- IPO Date
- Oct 31, 2019
- CIK
- 0001720725
- Website
- oysterpointrx.com
- Similar Companies
- Business
- Oyster Point Pharma, Inc. (OYST) operates as a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical therapies targeting ophthalmic diseases, particularly ocular surface conditions such as dry eye disease. The company's lead product, TYRVAYA (varenicline solution) nasal spray, represents the first FDA-approved nasal spray for the treatment of the signs and symptoms of dry eye disease; TYRVAYA functions as a nicotinic acetylcholine receptor agonist administered twice daily to stimulate natural tear production. Oyster Point maintains a pipeline including investigational nasal spray therapies in Phase II for neurotrophic keratopathy and preclinical candidates for conditions like vernal/atopic keratoconjunctivitis; operations target ophthalmologists and optometrists in the United States. Founded in 2015 and headquartered in Princeton, New Jersey, the company previously traded on NASDAQ under the ticker OYST with a field-based sales organization of 150-200 representatives. In January 2023, Viatris Inc. completed its acquisition of Oyster Point Pharma for approximately $424 million, including $11 per share in cash plus up to $2 per share in contingent value rights tied to performance milestones; this transaction establishes the foundation of Viatris' new ophthalmology franchise alongside the concurrent acquisition of Famy Life Sciences. Viatris projects these ophthalmology assets to generate over $1 billion in annual sales by 2028, supporting strategic expansion into ocular surface disease treatments amid its broader healthcare portfolio.
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
Why Viatris (VTRS) Is Buying Oyster Point (OYST)
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript
OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet
Oyster Therapeutics: State Of Business Is Confounding
Oyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call Transcript
OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript
OYSTER PT PHARM (OYST) Reports Q4 Loss, Tops Revenue Estimates
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2021 Results - Earnings Call Transcript
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021